PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.
SU11274 is a selective Met inhibitor with IC50 of 10 nM in cell-free assays, no effects on PGDFRβ, EGFR or Tie2.
Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and T...
Glesatinib?(MGCD265) is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively also inhibits Ron and Tie2. Phase 1/2.
SYN1143 is a potent and selective dual inhibitor ofc-Met/RON, with IC50s of 4 and 9nM, respectively. SYN1143 has weak inhibitory activity onLck,Tie2,Src, and BTKwith IC50s ranging from 160 to 710nM. SYN1143 can...
MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5nM.
Golvatinib (E-7050) is a potent dual inhibitor of bothc-Met and VEGFR2kinases with IC50s of 14 and 16nM, respectively.
JNJ-38877618 is a potent, highly selective, orally bioavailableMetkinase inhibitor with IC50s of 2 and 3nM for wild type and mutant Met, respectively.
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.in vitro: JNJ-38877605 shows more than 600-fold selectivity for c-Met...
PF-04217903 is a potent ATP-competitivec-Met kinaseinhibitor with Kiof 4.8nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.
PF-04217903 methanesulfonate is a potent ATP-competitivec-Met kinaseinhibitor with Kiof 4.8nM for human c-Met. PF-04217903 methanesulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic propertie...
MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1nM Wt c-Met) under investigation as a treatment for cancer.
SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1.
BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, ...
Capmatinib (INCB28060) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Phase 1.
Tepotinib (EMD 1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Phase 1.
SAR125844 is a potent intravenously active and highly selective MET kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D12...
TELL : +86-020-31703347
Add:Room 519, Block F, Guangzhou International Business Incubator, No.3 Lanyue Road, Science Town, Huangpu District, Guangzhou, China.
ULS products are chemical reagents for Research Use Only！Copyright © 2020-2021 ULS. All Rights Reserved.